Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00259532
Status:
UNKNOWN
Last Update Posted:
2009-02-26
First Post:
2005-11-25
Brief Title:
Three New Methods for Diagnosing Pancreas Cancer
Sponsor:
University of Copenhagen
Organization:
University of Copenhagen
Study Overview
Official Title:
Ultrasound With Contrast Agent 64-Slice-CT and Tumormarkers for Diagnosing Evaluation of Operability and Treatment Control of Pancreas Cancer
Status:
UNKNOWN
Status Verified Date:
2009-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this project is to evaluate and compare three new methods for diagnosis staging operability evaluation and treatment control of pancreas cancer The investigators use contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin which triggers the enzyme production of pancreas The hormones induce an increased metabolism and thus an increased blood flow through healthy pancreas tissue however not in tumor tissue The investigators hope to be able to use this effect diagnostically The patients included will also have a 64-slice-CT in order to evaluate if an increased diagnostic safety can be reached compared to an older CT scanning method All patients will also be examined for the tumor marker CA 19-9 Further the investigators will examine if contrast-enhanced ultrasound can contribute with information in treatment control after either surgery or medical treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None